All In Biotech

Drug Trial Radar · NCT04170153

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

161

Actual

Start

Dec 20, 2019

Primary completion

Oct 14, 2026

Study completion Oct 14, 2026

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Nov 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and early signs of efficacy of Tuvuseritib (M1774) as monotherapy and in combination with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib.

Conditions

  • Metastatic or Locally Advanced Unresectable Solid Tumors

Interventions

  • M1774Drug

    M1774 will be administered orally throughout the study.

  • NiraparibDrug

    Niraparib will be administered orally throughout the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A1, A4 and A5: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation PeriodTime frame: Day 1 to Day 21 of Cycle 1 (Each Cycle is of 21 days)
  2. Part A1, A3, A4, A5 and B1: Occurrence of Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (AEs) and Death According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0Time frame: Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years
  3. Part A1, A3, A4, A5 and B1: Number of Participants With Grade 3 or Higher Laboratory Findings According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0Time frame: Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years
  4. Part A1, A3, A4, A5 and B1: Number of Participants With Abnormalities in Vital SignsTime frame: Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years
  5. Part A1, A3, A4, A5 and B1: Number of Participants With Clinical Significant Abnormalities in Electrocardiogram (ECG) FindingsTime frame: Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years
  6. Part A2: Area Under the Plasma Concentration Curve From Time Zero to 24 Hours Post Dose (AUC 0-24h) of Tuvusertib (M1774)Time frame: Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)
  7. Part A2: Area Under the Plasma Concentration Curve From Time Zero to Infinity Post Dose (AUC 0-inf) of Tuvusertib (M1774)Time frame: Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)
  8. Part A2: Maximum Observed Plasma Concentration (Cmax) of Tuvusertib (M1774)Time frame: Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)
  9. Part A2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve (Frel[AUC]) of Tuvusertib (M1774) Under Fed Condition as Compared to Fasting ConditionTime frame: Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)
  10. Part A2: Relative Bioavailability Based on Maximum Observed Plasma Concentration (Frel[Cmax]) of Tuvusertib (M1774) Under Fed Condition as Compared to Fasting ConditionTime frame: Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)
  11. Part A3: Objective Response as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Baseline up to 2.2 years
  12. Part B1: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation PeriodTime frame: Day 1 to Day 28 of Cycle 1 (Each Cycle is of 28 days)
  13. Part A1, A4, A5 and B1: To Determine the Recommended Dose Expansion (RDE) for Tuvusertib (M1774) monotherapy globally, in Japanese and in Chinese participants With Metastatic or Locally Advanced Unresectable Solid Tumors and in combination with NiraparibTime frame: Assessed up to approximately 2.2 years

Locations

16 sites in 5 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • NEXT Oncology

    Austin, Texas

  • Mary Crowley Cancer Research Centers

    Dallas, Texas

  • The Methodist Hospital Research Institute

    Houston, Texas

  • University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics

    Houston, Texas

  • Beijing Cancer Hospital

    Beijing, China

  • National Cancer Center Hospital - Dept of Experimental Therapeutics

    Chūōku, Japan

  • National Cancer Center Hospital East - Dept of Experimental Therapeutics

    Kashiwa-shi, Japan

  • Hospital Clinic de Barcelona - Servicio de Oncologia

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron - Oncology Dept.

    Barcelona, Spain

  • Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica

    Madrid, Spain

  • Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica

    Valencia, Spain

  • Addenbrooke's Hospital - Dept of Oncology

    Cambridge, United Kingdom

  • The Christie Hospital - Dept of Oncology

    Manchester, United Kingdom

  • Northern Centre for Cancer Care - Sir Bobby Robson Cancer Trials Research Centre

    Newcastle upon Tyne, United Kingdom

  • Royal Marsden Hospital - Dept of Oncology

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.